{"id":33516,"date":"2025-06-02T13:02:25","date_gmt":"2025-06-02T11:02:25","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33516"},"modified":"2025-09-10T13:19:47","modified_gmt":"2025-09-10T11:19:47","slug":"umass-chan-licencja-sirna-technologie-a-m2ds","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/pl\/umass-chan-licencja-sirna-technologie-a-m2ds\/","title":{"rendered":"Nowy post\u0119p w poszukiwaniu leczenia: UMass Chan udziela licencji na technologi\u0119 siRNA \u00a0"},"content":{"rendered":"<p>UMass Chan School of Medicine udzieli\u0142a licencji na obiecuj\u0105c\u0105 technologi\u0119 opart\u0105 na siRNA firmie M2DS, start-upowi maj\u0105cemu na celu rozw\u00f3j tej technologii w leczeniu zespo\u0142u duplikacji genu MECP2. Oznacza to du\u017cy krok naprz\u00f3d w d\u0105\u017ceniu do zastosowania klinicznego.&nbsp;<\/p>\n\n\n\n<p>Technologia zosta\u0142a opracowana w laboratorium dr Khvorovej pod nadzorem Vignesha Hariharana. Wst\u0119pne badania zosta\u0142y sfinansowane przez Cure MDS i Rett Syndrome Research Trust. Dzia\u0142anie siRNA polega na namierzaniu i degradacji informacyjnego RNA odpowiedzialnego za nadprodukcj\u0119 bia\u0142ka MeCP2.&nbsp;<\/p>\n\n\n\n<p>W badaniach na myszach jedna dawka tego zwi\u0105zku skutecznie dociera\u0142a do m\u00f3zgu i rdzenia kr\u0119gowego i wymaga\u0142aby tylko jednego lub dw\u00f3ch poda\u0144 rocznie. Dzi\u0119ki licencjonowaniu tej technologii przez M2DS, kandydat na lek wchodzi obecnie w faz\u0119, w kt\u00f3rej mo\u017ce otrzyma\u0107 niezb\u0119dne wsparcie, aby przej\u015b\u0107 do bada\u0144 klinicznych na ludziach.&nbsp;&nbsp;<\/p>\n\n\n\n<p>Opr\u00f3cz trwaj\u0105cych bada\u0144 klinicznych prowadzonych przez Ionis i HuidaGene, ten wa\u017cny prze\u0142om mo\u017ce by\u0107 obiecuj\u0105cym dodatkiem do listy potencjalnych metod leczenia tej rzadkiej i z\u0142o\u017conej choroby.&nbsp;<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-white-color has-text-color has-background has-link-color wp-element-button\" href=\"https:\/\/bridge.umassmed.edu\/s\/news\/news-article\/umass-chan-licenses-sirna-therapeutics-for-mecp2-duplication-syndrome-MCMWKNCJYQ25CQHF5YITTOM757HU\" style=\"border-radius:11px;background-color:#f7a13f\">Zobacz komunikat prasowy<\/a><\/div>\n<\/div>\n\n\n\n<p><\/p>","protected":false},"excerpt":{"rendered":"<p>L&rsquo;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que [&hellip;]<\/p>","protected":false},"author":1,"featured_media":33517,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-33516","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2<\/title>\n<meta name=\"description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/pl\/umass-chan-licencja-sirna-technologie-a-m2ds\/\" \/>\n<meta property=\"og:locale\" content=\"pl_PL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Une nouvelle avanc\u00e9e dans la recherche d&#039;un traitement : l&#039;UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"L&#039;\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/pl\/umass-chan-licencja-sirna-technologie-a-m2ds\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-02T11:02:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T11:19:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Napisane przez\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Szacowany czas czytania\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuty\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"},\"wordCount\":245,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"url\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\",\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"datePublished\":\"2025-06-02T11:02:25+00:00\",\"dateModified\":\"2025-09-10T11:19:47+00:00\",\"description\":\"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\"},\"inLanguage\":\"pl-PL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pl-PL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pl-PL\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nowy prze\u0142om w poszukiwaniu leczenia: UMass Chan licencjonuje technologi\u0119 siRNA - DupMECP2","description":"UMass Chan School of Medicine udzieli\u0142a licencji na obiecuj\u0105c\u0105 technologi\u0119 opart\u0105 na siRNA firmie M2DS, start-upowi maj\u0105cemu na celu rozw\u00f3j tej technologii w leczeniu zespo\u0142u duplikacji genu MECP2. Oznacza to du\u017cy krok naprz\u00f3d w d\u0105\u017ceniu do zastosowania klinicznego.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/pl\/umass-chan-licencja-sirna-technologie-a-m2ds\/","og_locale":"pl_PL","og_type":"article","og_title":"Une nouvelle avanc\u00e9e dans la recherche d'un traitement : l'UMass Chan octroie une licence pour la technologie siRNA \u00a0 - DupMECP2","og_description":"L'\u00e9cole de m\u00e9decine UMass Chan a octroy\u00e9 une licence pour une technologie prometteuse bas\u00e9e sur le siRNA \u00e0 M2DS, une start-up visant \u00e0 faire progresser cette technologie en tant que traitement du syndrome de duplication du g\u00e8ne MECP2. Cela marque une avanc\u00e9e majeure dans la poursuite vers une application clinique.","og_url":"https:\/\/dupmecp2.eu\/pl\/umass-chan-licencja-sirna-technologie-a-m2ds\/","og_site_name":"DupMECP2","article_published_time":"2025-06-02T11:02:25+00:00","article_modified_time":"2025-09-10T11:19:47+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Napisane przez":"Caroline","Szacowany czas czytania":"2 minuty"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"Une nouvelle avanc\u00e9e dans la recherche d&rsquo;un traitement : l&rsquo;UMass Chan octroie une licence pour la technologie siRNA \u00a0","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"},"wordCount":245,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","articleSection":["Actualit\u00e9"],"inLanguage":"pl-PL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","url":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/","name":"Nowy prze\u0142om w poszukiwaniu leczenia: UMass Chan licencjonuje technologi\u0119 siRNA - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","datePublished":"2025-06-02T11:02:25+00:00","dateModified":"2025-09-10T11:19:47+00:00","description":"UMass Chan School of Medicine udzieli\u0142a licencji na obiecuj\u0105c\u0105 technologi\u0119 opart\u0105 na siRNA firmie M2DS, start-upowi maj\u0105cemu na celu rozw\u00f3j tej technologii w leczeniu zespo\u0142u duplikacji genu MECP2. Oznacza to du\u017cy krok naprz\u00f3d w d\u0105\u017ceniu do zastosowania klinicznego.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb"},"inLanguage":"pl-PL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/"]}]},{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/SiRNA-UMASS.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/umass-chan-licence-sirna-technologie-a-m2ds\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"Une nouvelle avanc\u00e9e dans la recherche d&#8217;un traitement : l&#8217;UMass Chan octroie une licence pour la technologie siRNA \u00a0"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pl-PL"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"pl-PL","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/pl\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33516","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/comments?post=33516"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33516\/revisions"}],"predecessor-version":[{"id":33521,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/posts\/33516\/revisions\/33521"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media\/33517"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/media?parent=33516"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/categories?post=33516"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/pl\/wp-json\/wp\/v2\/tags?post=33516"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}